[1]黄丽娟,王立凯,胡芳,等.肿瘤M2型-丙酮酸激酶单克隆抗体的制备及免疫放射分析方法的建立[J].国际放射医学核医学杂志,2012,36(3):134-137.[doi:10.3760/cma.j.issn.1673-4114.2012.03.002]
　HUANG Li-juan,WANG Li-kai,HU Fang,et al.Preparation of the monoclonal antibodies against tumor M2-type pyruvate kinase and establishment of immunoradiometric analysis for detection[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(3):134-137.[doi:10.3760/cma.j.issn.1673-4114.2012.03.002]
点击复制

肿瘤M2型-丙酮酸激酶单克隆抗体的制备及免疫放射分析方法的建立(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
36
期数:
2012年第3期
页码:
134-137
栏目:
实验核医学
出版日期:
2012-05-25

文章信息/Info

Title:
Preparation of the monoclonal antibodies against tumor M2-type pyruvate kinase and establishment of immunoradiometric analysis for detection
作者:
黄丽娟1;  王立凯2;  胡芳2;  孟涛1;  魏丙卓1;  张志洋1
1. 天健生物制药(天津)有限公司, 天津 300457;
2. 天津市协和医药科技集团有限公司, 天津 300192
Author(s):
HUANG Li-juan1;  WANG Li-kai2;  HU Fang2;  MENG Tao1;  WEI Bing-zhuo1;  ZHANG Zhi-yang1
TianJian Biotechnologies(Tianjin) Limited Company, Tianjin 300457, China
关键词:
丙酮酸激酶; 抗体; 单克隆; 免疫放射分析
Keywords:
Pyruvate kinase; Antibodies;  monoclonal; Immunoradiometric assay
DOI:
10.3760/cma.j.issn.1673-4114.2012.03.002
摘要:
目的 制备肿瘤M2型-丙酮酸激酶(M2-PK)单克隆抗体,并建立免疫放射分析的检测方法。方法 用肿瘤M2-PK抗原免疫小鼠,经细胞融合及筛选后得到一对单克隆抗体,建立免疫放射分析的方法,并评价该检测方法的灵敏度、特异度及精密度。结果 获得了1A6和3F8两株效价高、特异度好的单克隆抗体,建立了双抗体夹心免疫放射分析方法。该检测方法的分析灵敏度为2U/ml,临床灵敏度和特异度分别为70.5%和89.O%,提供的M2.PK的正常参考值范围是<14.8U/ml,批内不精密度<5%,批间不精密度<10%。结论 建立的双抗体夹心免疫放射分析法可用于体检筛查及肿瘤患者的早期诊断,做到尽早治疗,提高患者的生存质量。
Abstract:
Objective To produce monoclonal antibodies against tumor M2-type pyruvate kinase (M2-PK), and to establish immunoradiometric analysis for detection. Methods The BALB/c mice were immunized with M2-PK antigen. Monoclonal antibodies were generated after cell fusion and screening. Established detection method of immunoradiometric analysis and then evaluated its sensitivity, specificity and coefficient of variation. Results Two monoclonal antibodies (1A6 and 3F8) with high-titer and high-pecificity were generated and detection method of immunoradiometric analysis was established. The analytical sensitivity of immunoradiometric analysis was 2 U/ml, while its clinical sensitivity and specificity was 70.5% and 89.0% respectively. The reference value of M2-PK level was less than 14.8 U/ml according to immunoradiometric analysis. Intra-assay coefficient of variation was less than 5%, while inter-assay coefficient of variation was less than 10%. Conclusion This sensitive immunoradiometric analysis can be used in early diagnosis of tumor and physical examination.

参考文献/References:

[1] Mazurek S,Boschek CB,Hugo F,et al.Pyruvate kinase type M2 and its role in tumor growth and spreading.Semin Cancer Biol,2005,15(4):300-308.
[2] Hardt PD,Ewald N.Tumor M2 pyruvate kinase:a tumor marker and its clinical application in gastrointestinal malignancy.Expert Rev Mol Diagn,2008,8(5):579-585.
[3] Weinberger R,Appel B,Stein A,et al.The pyruvate kinase isoenzyme M2(Tu M2-PK) as a tumour marker for renal cell carcinoma.Eur J Cancer Care (Engl),2007,16(4):333-337.
[4] 丁志祥,解东涯,杨春秀,等.血浆TU M2-PK检测对肺癌的诊断价值.第二军医大学学报,2006,27(2):219-220.
[5] Kumar Y,Tapuria N,Kirmani N,et al.Tumour M2-pyruvate kinase:a gastrointestinal cancer marker.Eur J Gastroenterol Hepatol,2007,19(3):265-276.
[6] 禹立霞,刘宝瑞,王立峰,等.胃肠肿瘤术后Tu M2-PK含量的变化.实用医技杂志,2006,13(3):350-352.

相似文献/References:

[1]王立凯,黄丽娟,潘学继,等.人附睾蛋白4单克隆抗体与免放试剂盒的制备及其对卵巢癌诊断的临床价值探讨[J].国际放射医学核医学杂志,2016,40(3):183.[doi:10.3760/cma.j.issn.1673-4114.2016.03.005]
　Wang Likai,Huang Lijuan,Pan Xueji,et al.Preparation of monoclonal antibodies and immunoradiometric assay kit against human epididymis protein 4 and its clinical value in diagnosis of ovarian cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):183.[doi:10.3760/cma.j.issn.1673-4114.2016.03.005]
[2]汪文霞,兰晓莉,张永学.HER2的表达及其分子影像的研究进展[J].国际放射医学核医学杂志,2016,40(5):363.[doi:10.3760/cma.j.issn.1673-4114.2016.05.007]
　Wang Wenxia,Lan Xiaoli,Zhang Yongxue.Research and development of HER2 expression molecular imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):363.[doi:10.3760/cma.j.issn.1673-4114.2016.05.007]
[3]杨卫东,汪静.肿瘤核素靶向治疗新进展[J].国际放射医学核医学杂志,2015,39(1):19.[doi:10.3760/cma.j.issn.1673-4114.2015.01.006]
　Yang Weidong,Wang Jing.Advance progress of radionuclide target tumor therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):19.[doi:10.3760/cma.j.issn.1673-4114.2015.01.006]
[4]刘岩,杨爱民,欧阳雁,等.放射性核素唾液腺显像及抗核抗体联合检查在干燥综合征中的诊断价值[J].国际放射医学核医学杂志,2014,38(4):219.[doi:10.3760/cma.j.issn.1673-4114.2014.04.003]
　Liu Yan,Yang Aimin,Ou Yangyan,et al.The diagnostic value of joint inspection of radionuclide salivary gland scintigraphy and antinuclear antibody examination in Sjögren’s syndrome patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(3):219.[doi:10.3760/cma.j.issn.1673-4114.2014.04.003]
[5]郭艾楠,魏玲格,傅鹏.131I-肿瘤细胞核人鼠嵌合单克隆抗体治疗实体瘤的研究进展[J].国际放射医学核医学杂志,2013,37(2):120.[doi:10.3760/cma.j.issn.1673-4114.2013.02.015]
　GUO Ai-nan,WEI Ling-ge,FU Peng.Advances on the treatment of solid tumor by 131I labeled mouse-human chimeric tumor necrosis therapy monoclanal antibody[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(3):120.[doi:10.3760/cma.j.issn.1673-4114.2013.02.015]
[6]张建媛,缪蔚冰.电化学发光法与放射性受体分析法检测促甲状腺激素受体抗体的对比研究[J].国际放射医学核医学杂志,2012,36(1):20.[doi:10.3760/cma.j.issn.1673-4114.2012.01.005]
　ZHANG Jian-yuan,MIAO Wei-bing.Comparative study between electrochemiluminescence immunoassay and radioactive receptor assay in measurement of serum thyrotropin receptor antibody[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(3):20.[doi:10.3760/cma.j.issn.1673-4114.2012.01.005]
[7]姚红霞,张金山.微波消融和131I-肿瘤细胞核人鼠嵌合单克隆抗体联合治疗肺癌[J].国际放射医学核医学杂志,2012,36(5):264.[doi:10.3760/cnla.j.issn.1673-4114.2012.05.002]
　YAO Hong-xia,ZHA NG Jin-shan.Combination of microwave ablation and 131I labeled tumor necrosis therapy chimeric antibody in the treatment of lung cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(3):264.[doi:10.3760/cnla.j.issn.1673-4114.2012.05.002]
[8]钟兴祥,郑吉祥,蓝冠章,等.Graves甲亢131I治疗前后血清TRAb动态变化及临床价值[J].国际放射医学核医学杂志,2011,35(2):110.[doi:10.3760/cma.j.issn.1673-4114.2011.02.011]
　ZHONG Xing-xiang,ZHENG Ji-xiang,LAN Guan-zhang,et al.Changes of serum TRAb after 131I radiotherapy in patients of Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(3):110.[doi:10.3760/cma.j.issn.1673-4114.2011.02.011]
[9]蒋宁一,熊玥.放射免疫导向治疗真菌感染灶的研究[J].国际放射医学核医学杂志,2008,32(3):137.
　JIANG Ning-yi,XIONG Yue.Research about the radioimmunotherapy of fungal infection[J].International Journal of Radiation Medicine and Nuclear Medicine,2008,32(3):137.
[10]李楠,李培勇.放射性碘间接标记抗体方法的研究进展[J].国际放射医学核医学杂志,2008,32(5):260.
　LI Nan,LI Pei-yong.The recent development of the strategy for indirect antibody radiolabel with iodine[J].International Journal of Radiation Medicine and Nuclear Medicine,2008,32(3):260.

备注/Memo

备注/Memo:
收稿日期:2012-03-11。
通讯作者:黄丽娟(Email:tech@tj-bio.com)
更新日期/Last Update: 1900-01-01